Navigation Links
Axial Biotech Meets Major Scientific Milestones; Receives $6 Million Tranche of Series B Financing
Date:3/17/2008

SALT LAKE CITY, March 17 /PRNewswire/ -- Axial Biotech, Inc., a company revolutionizing spine care through the development of molecular diagnostics and motion preserving technologies, announced today that it has met several major scientific milestones in its development of the first genetic prognostic test for Adolescent Idiopathic Scoliosis (AIS) and has closed a $6 million tranche of its Series B financing. The Series B financing was led by Johnson & Johnson Development Corporation, with participation by vSpring Capital and Ohio Biotech Group.

"These scientific milestones were extremely rigorous," said Kenneth Ward, M.D., the Chairman and Chief Scientific Officer of Axial Biotech. "They required our scientific team to analyze data from thousands of individuals and to confirm the identity of specific genetic markers that predict curve progression in early stage AIS with an extraordinary degree of accuracy, sensitivity, and specificity."

"I am very pleased about our team's accomplishments and for the continued support of our investors," said John M. Climaco, Axial Biotech's President and CEO. "For surgeons, patients, and their families, the significance of a genetic prognostic test for AIS, which can discriminate between progressive and non-progressive cases of the disease, is difficult to overestimate. It will positively impact the lives of thousands of children and should provide a springboard for the development of future scoliosis treatment options and may include the use of the company's motion preserving technologies."

"Axial Biotech's achievement of these very challenging milestones represents one of the largest steps in the company's efforts to bring important diagnostic tools to the orthopedic clinic," stated Dinesh Patel, Managing Director, vSpring Capital. "Our latest investment can be viewed as a clear vote of confidence, in the role that molecular diagnostics will play, in advancing the treatment of spinal disorders."

Axial Biotech is the first company to pursue DNA-based predictive tests for common spinal conditions. In addition to its groundbreaking work with AIS, Axial Biotech has also initiated clinical studies in the development of genetic tests for other common spinal diseases. Axial Biotech expects to launch its genetic prognostic test for AIS in September, 2008.

About Axial Biotech, Inc.

Axial Biotech, Inc. is a privately held, venture-backed company founded in 2002 by a group of internationally recognized spine surgeons and geneticists. The company is focused on developing and commercializing DNA-based pre-symptomatic and prognostic tests, as well as motion-preserving technologies, for common spinal disorders. The company's headquarters and laboratory are located in Salt Lake City, Utah.

About Johnson & Johnson Development Corporation.

Organized in 1973, Johnson & Johnson Development Corporation (JJDC) is the venture capital subsidiary of Johnson & Johnson. JJDC makes private equity investments in venture funded health care companies. Portfolio companies include those in the fields of pharmaceuticals, biotechnology, medical devices, diagnostics, and consumer products.

About vSpring Capital

vSpring Capital (http://www.vspring.com) is an early-stage venture capital firm with $350 million under management. With offices in Utah, New Mexico and Colorado, vSpring invests in information technology and life science companies that have the potential to transform their markets and create lasting value.

About Ohio Biotech Group

Ohio Biotech Group is a group of angel investors that include some of the leading spine surgeons in the United States.


'/>"/>
SOURCE Axial Biotech, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Oncolytics Biotech Inc. Collaborators to Present Reovirus Research at AACR Annual Meeting
2. Altogen Biosystems Launches Custom Biotechnology Research Services: Generation of Stable Cell Lines and RNAi Cell Transfection Services
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioSquare 2008
4. A Communitys Fight to Preserve its Historical and Rural Culture in Virginia: Biotechnology CEO Gets Involved
5. Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa)
6. Biotechnology Leader to Exhibit at Upcoming Trade Show
7. Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007
8. New Books on Best Practices in Biotechnology Business Development and Biotechnology Education
9. Tunnell Consulting Expands Biotechnology Expertise
10. Biotech Drops Amid Tough Markets in February
11. Genetic Engineering & Biotechnology News reports on advances in miRNA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. ... test has received AOAC Research Institute approval 061601. , “This is another AOAC-RI ... stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... STACS DNA ... Technical Leader at the Arkansas State Crime Laboratory, has joined STACS DNA as a ... STACS DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further ...
(Date:6/23/2016)... , June 23, 2016 On ... session at 4,833.32, down 0.22%; the Dow Jones Industrial Average ... 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ), Aralez ... Inc. (NASDAQ: BIND ). Learn more about these ...
(Date:6/23/2016)... , June 23, 2016 ... market research report to its pharmaceuticals section with ... product details and much more. Complete ... across 151 pages, profiling 15 companies and supported ... at http://www.reportsnreports.com/reports/601420-global-cell-culture-media-industry-2016-market-research-report.html . The ...
Breaking Biology Technology:
(Date:6/15/2016)... York , June 15, 2016 ... new market report titled "Gesture Recognition Market by Application ... Forecast, 2016 - 2024". According to the report, the  ... 11.60 billion in 2015 and is estimated to ... USD 48.56 billion by 2024.  Increasing ...
(Date:6/7/2016)... 7, 2016  Syngrafii Inc. and San Antonio ... that includes integrating Syngrafii,s patented LongPen™ eSignature "Wet" ... collaboration will result in greater convenience for SACU ... while maintaining existing document workflow and compliance requirements. ... Highlights: ...
(Date:6/2/2016)... 2, 2016   The Weather Company , an IBM ... an industry-first capability in which consumers will be able to ... ask questions via voice or text and receive relevant information ... Marketers have long sought an advertising solution that ... be personal, relevant and valuable; and can scale across millions ...
Breaking Biology News(10 mins):